Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU4-35P (RNA, U4 small nuclear 35, pseudogene) is classified as a pseudogene of the U4 small nuclear RNA gene family. U4 snRNAs are components of the major spliceosome complex, which is essential for the splicing of precursor mRNA in eukaryotic cells. However, as a pseudogene, RNU4-35P does not produce a functional RNA product and is not known to contribute directly to biological processes, disease mechanisms, or serve as a drug target. This distinguishes it from functional U4 snRNA genes like RNU4-2, which have been implicated in neurodevelopmental disorders when mutated. There is no evidence that RNU4-35P is involved in any known signaling pathway, disease process, drug mechanism, or biomarker application. Key points: - RNU4-35P is a pseudogene (non-functional remnant of a gene) and is not a direct therapeutic or biological target. - It should not be confused with functional snRNA genes (such as RNU4-2) that can be implicated in disease when mutated. If you are looking for information relevant to spliceosome-related diseases, refer instead to functional U4 snRNA genes (like RNU4-2).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 35, pseudogene (RNU4-35P).